FDA OKs Sacituzumab Govitecan for HR+ Metastatic Breast Cancer FDA OKs Sacituzumab Govitecan for HR+ Metastatic Breast Cancer
Investigators reported an overall survival benefit of 3.2 months versus single agent chemotherapy in previously treated patients.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news